Improving Outcomes For Men With Prostate Cancer Through More Accurate Imaging

Monday Lunch Livestream

With Professor Michael Hofman, Nuclear Medicine Physician at the Peter MacCallum Cancer Centre.

9 August 2021

Professor Michael Hofman presents findings and outcomes from the Lancet (2020) published and ACTA (2021) award-winning proPSMA study in which 300 men with newly diagnosed prostate cancer participated. Each participant had a whole-body 3D scan using a radioactive substance that detects a molecule called prostate-specific membrane antigen (PSMA), which is readily found on the surface of prostate cancer cells. This was then followed by a PET/CT scan that produced detailed images of the cancer spread. The trial team found that PSMA PET/CT had an accuracy of 92% compared to 65% accuracy achieved with conventional imaging.

Professor Hofman

Professor Hofman is a nuclear medicine physician, physician-scientist and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at the Peter MacCallum Cancer Centre in Melbourne. He previously completed a research fellowship at Guy's & St Thomas' in London. He has broad research interest in radiopharmaceuticals for imaging and therapy (theranostics) in oncology. This includes neuroendocrine tumours and haematologic applications and more recently he has focussed on improving outcomes for men with prostate cancer.

This presentation is suitable for non-medical, medical and allied health audiences with limited knowledge of PSMA.